Uninvestigated Dyspepsia and Heartburn Overlap Syndrome at Industrial Hub of Eastern Siberia

Aim. A study of the overlap syndrome of uninvestigated dyspepsia and heartburn at an industrial hub city of Eastern Siberia.
Materials and methods. A total of 1,382 subjects (684 men and 698 women, mean age 40.6 years) were randomly selected and examined for the central district of Krasnoyarsk. The clinical check-up and interviewing results were registered with a standard questionnaire. Heartburn was diagnosed as per the Montreal Consensus. Since no endoscopic patient examination had been performed, dyspepsia was assumed uninvestigated. Dyspepsia was diagnosed as per the Rome IV criteria. The study conduction complied with ethical standards. Each participant signed an informed examination consent, in accordance to the regulations by the World Medical Association’s Declaration of Helsinki. The survey data were analysed with common statistical methods.
Results. Heartburn, uninvestigated dyspepsia and their overlap syndrome had prevalence of 12.4, 21.1 and 5% in study population, respectively. Uninvestigated dyspepsia was registered in 40.4% patients with and 18.4% — without heartburn (p < 0.001). The risk factors of overlap syndrome were age >40 years (p = 0.002), obesity (p = 0.002), nonsteroidal anti-inflammatory drug and/or aspirin intake (p = 0.004) and tobacco smoking (p = 0.007). Among total patients with the heartburn/uninvestigated dyspepsia overlap syndrome, only 33.3% systemically had proton pump inhibitors, and only 17.4% had a prokinetic therapy.
Conclusion. The heartburn/uninvestigated dyspepsia overlap syndrome is an actual issue in the Krasnoyarsk population. Attention is warranted to this problem to optimise treatment and prevention measures.

1. Geeraerts A., Van Houtte B., Clevers E., Geysen H., Vanuytsel T., Tack J., et al. Gastroesophageal Reflux Disease-Functional Dyspepsia Overlap: Do Birds of a Feather Flock Together? Am J Gastroenterol. 2020;115(8):1167–82. DOI: /10.14309/ajg.0000000000000619

2. Wauters L., Talley N.J., Walker M.M., Tack J., Vanuytsel T. Novel concepts in the pathophysiology and treatment of functional dyspepsia. Gut. 2020;69(3):591–600. DOI: 10.1136/gutjnl-2019-318536

3. Ford A.C., Mahadeva S., Carbone M.F., Lacy B.E., Talley N.J. Functional dyspepsia. Lancet. 2020;396(10263):1689–702. DOI: 10.1016/S0140-6736(20)30469-4

4. Tack J., Schol J., Van den Houte K., Huang I.H., Carbone F. Paradigm Shift: Functional Dyspepsia-A “Leaky Gut” Disorder? Am J Gastroenterol. 2021;116(2):274–5. DOI: 10.14309/ajg.0000000000001077

5. Takeuchi T., Takahashi Y., Kawaguchi S., Ota K., Harada S., Kojima Y. et al. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. J Gastroenterol Hepatol. 2018;33(3):623–30. DOI: 10.1111/jgh.13970

6. Paniotto V.I., Maksimenko V.S. Quantitative methods in sociological research. Kiev: health; 2003. 270 p. (In Russ.)

7. Vakil N., van Zanten S.V., Kahrilas P., Dent J., Jones R.; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidencebased consensus. Am J Gastroenterol. 2006;101(8):1900–20. DOI: 10.1111/j.1572-0241.2006.00630.x

8. Talley N.J., Vakil N.B., Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology. 2005;129(5):1756–80. DOI: 10.1053/j.gastro.2005.09.020

9. Stanghellini V., Chan F.K., Hasler W.L., Malagelada J.R., Suzuki H., Tack J., Talley N.J. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380–92. DOI: 10.1053/j.gastro.2016.02.011

10. Eusebi L.H., Ratnakumaran R., Yuan Y., SolaymaniDodaran M., Bazzoli F., Ford A.C. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–40. DOI: 10.1136/gutjnl-2016-313589

11. Richter J.E., Rubenstein J.H. Presentation and Epidemiology of Gastroesophageal Reflux Disease. Gastroenterology. 2018;154(2):267–76. DOI: 10.1053/j.gastro.2017.07.045

12. Lazebnik L.B., Masharova A.A., Bordin D.S., Vasiliev Yu.V., Tkachenko E.I., Abdulkhakov R.A., et al. Results of a multicenter trial “Epidemiology of Gastroesophageal Reflux Disease in Russia” (MEGRE). Terapevticheskij arkhiv. 2011;83(1):45–50 (In Russ.).

13. Ford A.C., Marwaha A., Sood R., Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut. 2015;64(7):1049–57. DOI: 10.1136/gutjnl-2014-307843

14. Barberio B., Mahadeva S., Black C.J., Savarino E.V., Ford A.C. Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. Aliment Pharmacol Ther. 2020;52(5):762–73. DOI: 10.1111/apt.16006

15. Tsukanov V.V., Vasyutin A.V., Tonkikh J.L. Prevalence, risk factors, and ethnic characteristics of uninvestigated dyspepsia. Russkiy meditsinskiy zhurnal. Meditsinskoye obozreniye. 2020;4(5):263–67 (In Russ.). DOI: 10.32364/2587-6821-2020-4-5-263-267

16. Talley N.J., Holtmann G., Agreus L., Jones M. Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: a four nations study. Am J Gastroenterol. 2000;95(6):1439–47. DOI: 10.1111/j.1572-0241.2000.02075.x

17. Locke G.R., Zinsmeister A.R., Fett S.L., Melton L.J., Talley N.J. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil. 2005;17(1):29–34. DOI: 10.1111/j.1365-2982.2004.00581.x

18. Ohara S., Kawano T., Kusano M., Kouzu T. Survey on the prevalence of GERD and FD based on the Montreal definition and the Rome III criteria among patients presenting with epigastric symptoms in Japan. J Gastroenterol. 2011;46(5):603–11. DOI: 10.1007/s00535-011-0382-1

19. Choung R.S., Locke G.R., Schleck C.D., Zinsmeister A.R., Talley N.J. Overlap of dyspepsia and gastroesophageal reflux in the general population: one disease or distinct entities? Neurogastroenterol Motil. 2012;24(3):229–34, e106. DOI: 10.1111/j.1365-2982.2011.01845.x

20. Min B.H., Huh K.C., Jung H.K., Yoon Y.H., Choi K.D., Song K.H. et al. Prevalence of uninvestigated dyspepsia and gastroesophageal reflux disease in Korea: a population-based study using the Rome III criteria. Dig Dis Sci. 2014;59(11):2721–9. DOI: 10.1007/s10620-014-3243-y

21. Rasmussen S., Jensen T.H., Henriksen S.L., Haastrup P.F., Larsen P.V., Søndergaard J., et al. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol. 2015;50(2):162–9. DOI: 10.3109/00365521.2014.983157

22. Gerson L.B., Kahrilas P.J., Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastroenterol Hepatol. 2011;9(10):824–33. DOI: 10.1016/j.cgh.2011.05.015

23. Lee S.W., Lee T.Y., Lien H.C., Yeh H.Z., Chang C.S., Ko C.W. The risk factors and quality of life in patients with overlapping functional dyspepsia or peptic ulcer disease with gastroesophageal reflux disease. Gut Liver. 2014;8(2):160–4. DOI: 10.5009/gnl.2014.8.2.160

24. Fujiwara Y., Kubo M., Kohata Y., Machida H., Okazaki H., Yamagami H., et al. Cigarette smoking and its association with overlapping gastroesophageal reflux disease, functional dyspepsia, or irritable bowel syndrome. Intern Med. 2011;50(21):2443–7. DOI: 10.2169/internalmedicine.50.6012

25. Bhat S., Varghese C., Carson D.A., Hayes T.C.L., Gharibans A.A., Andrews C.N., O’Grady G. Gastric dysrhythmia in gastroesophageal reflux disease: a systematic review and meta-analysis. Esophagus. 2021. Online ahead of print. DOI: 10.1007/s10388-021-00820-6

26. Sharma P., Yadlapati R. Pathophysiology and treatment options for gastroesophageal reflux disease: looking beyond acid. Ann N Y Acad Sci. 2021;1486(1):3–14. DOI: 10.1111/nyas.14501

27. Funaki Y., Ogasawara N., Kawamura Y., Yoshimine T., Tamura Y., Izawa S. et al. Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study. Neurogastroenterol Motil. 2020;32(2):e13749. DOI: 10.1111/nmo.13749

28. Isshi K., Furuhashi H., Nakada K. Therapeutic strategy for the patients with coexisting gastroesophageal reflux disease and postprandial distress syndrome of functional dyspepsia. JGH Open. 2020;4(4):582–8. DOI: 10.1002/jgh3.12299

29. Ivashkin V.T., Mayev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M. et al. Diagnosis and treatment of the functional dyspepsia: Clinical Guidelines of the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):50–61 (In Russ.). DOI: 10.22416/1382-4376-2017-27-1-50-61

30. Ivashkin V.T., Shelygin Yu.A., Baranskaya E.K., Belousova E.A., Beniashvili A.G., Vasilyev S.V., et al. Diagnosis and treatment of the irritable bowel syndrome: Clinical Guidelines of the Russian Gastroenterological Association and Russian Association of Coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76–93 (In Russ.). DOI: 10.22416/1382-4376-2017-27-5-76-93

31. Ivashkin V.T., Mayev I.V., Trukhmanov A.S., Baranskaya Ye.K., Dronova O.B., Zayrat’yants O.V., et al. Diagnostics and treatment of gastroesophageal reflux disease: Clinical Guidelines of the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):75–95 (In Russ.). DOI: 10.22416/1382-4376-2017-27-4-75-95